Applied Therapeutics, Inc. (APLT)
After hours:
| Previous Close | 9.27 |
| Open | 9.44 |
| Bid | 9.57 x 300 |
| Ask | 9.67 x 600 |
| Day's Range | 8.95 - 9.64 |
| 52 Week Range | 1.79 - 10.62 |
| Volume | |
| Avg. Volume | 2,701,156 |
| Market Cap | 1.12B |
| Beta (5Y Monthly) | 2.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.42 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.67 |
GlobeNewswireApplied Therapeutics Reports Third Quarter 2024 Financial Results
- NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in Q1 2025 - NDA submission for govorestat for the treatment of SORD Deficiency under Accelerated Approval expected in early Q1 2025 NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug can
- GlobeNewswire
Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024, at 7:15 a.m. PT in Rancho Palos Verdes, California. A live webcast for this event will be accessible on the Events page under the I
